ES2835274T3 - Composiciones farmacéuticas que contienen un antagonista de la integrina alfa 4 para el tratamiento de afecciones inflamatorias oculares - Google Patents
Composiciones farmacéuticas que contienen un antagonista de la integrina alfa 4 para el tratamiento de afecciones inflamatorias oculares Download PDFInfo
- Publication number
- ES2835274T3 ES2835274T3 ES16736636T ES16736636T ES2835274T3 ES 2835274 T3 ES2835274 T3 ES 2835274T3 ES 16736636 T ES16736636 T ES 16736636T ES 16736636 T ES16736636 T ES 16736636T ES 2835274 T3 ES2835274 T3 ES 2835274T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- eye
- certain embodiments
- treatment
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)C[C@@](C(N[C@@](Cc(cc1)ccc1OC(N(CC1)CCC1C(*)=O)=O)C(O)=O)=O)NC(COc1c(C)cccc1)=O Chemical compound CC(C)C[C@@](C(N[C@@](Cc(cc1)ccc1OC(N(CC1)CCC1C(*)=O)=O)C(O)=O)=O)NC(COc1c(C)cccc1)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189813P | 2015-07-08 | 2015-07-08 | |
| PCT/IB2016/054073 WO2017006272A1 (en) | 2015-07-08 | 2016-07-07 | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2835274T3 true ES2835274T3 (es) | 2021-06-22 |
Family
ID=56373100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16736636T Active ES2835274T3 (es) | 2015-07-08 | 2016-07-07 | Composiciones farmacéuticas que contienen un antagonista de la integrina alfa 4 para el tratamiento de afecciones inflamatorias oculares |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10413535B2 (enExample) |
| EP (1) | EP3319639B1 (enExample) |
| JP (2) | JP6752276B2 (enExample) |
| KR (2) | KR102440162B1 (enExample) |
| CN (1) | CN107921136A (enExample) |
| AU (1) | AU2016290197B2 (enExample) |
| BR (1) | BR112018000112A2 (enExample) |
| CA (1) | CA2989522C (enExample) |
| CL (1) | CL2018000057A1 (enExample) |
| ES (1) | ES2835274T3 (enExample) |
| HK (1) | HK1247120A1 (enExample) |
| IL (2) | IL256770B (enExample) |
| MA (2) | MA42016A1 (enExample) |
| MX (1) | MX385229B (enExample) |
| MY (1) | MY187552A (enExample) |
| PL (1) | PL3319639T3 (enExample) |
| RU (1) | RU2018103940A (enExample) |
| TN (1) | TN2017000538A1 (enExample) |
| UA (1) | UA123728C2 (enExample) |
| WO (1) | WO2017006272A1 (enExample) |
| ZA (1) | ZA201708601B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165218A1 (en) | 2017-03-09 | 2018-09-13 | Allysta Pharmaceuticals, Inc | Peptides for dry eye disease |
| WO2018212846A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| JP2022541851A (ja) * | 2019-07-26 | 2022-09-27 | アレグロ ファーマシューティカルズ エルエルシー | 眼の非滲出型黄斑変性および他の障害を治療するためのペプチド |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| IL302175A (en) * | 2020-10-21 | 2023-06-01 | Azura Ophthalmics Ltd | Compounds and methods for the treatment of ocular disorders |
| KR102391198B1 (ko) * | 2021-08-27 | 2022-04-27 | 한림제약(주) | 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828074D0 (en) * | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0014892D0 (en) * | 2000-06-16 | 2000-08-09 | Glaxo Group Ltd | Novel pharmaceutical formulation |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| JP2009514969A (ja) * | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | 医学的状態を治療するための方法、組成物、およびキット |
| US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2016
- 2016-07-07 JP JP2018520045A patent/JP6752276B2/ja not_active Expired - Fee Related
- 2016-07-07 RU RU2018103940A patent/RU2018103940A/ru unknown
- 2016-07-07 BR BR112018000112-0A patent/BR112018000112A2/pt not_active Application Discontinuation
- 2016-07-07 KR KR1020187003454A patent/KR102440162B1/ko active Active
- 2016-07-07 EP EP16736636.8A patent/EP3319639B1/en active Active
- 2016-07-07 UA UAA201800954A patent/UA123728C2/uk unknown
- 2016-07-07 MX MX2017017163A patent/MX385229B/es unknown
- 2016-07-07 CN CN201680040066.0A patent/CN107921136A/zh active Pending
- 2016-07-07 AU AU2016290197A patent/AU2016290197B2/en not_active Ceased
- 2016-07-07 KR KR1020227015200A patent/KR20220062688A/ko not_active Ceased
- 2016-07-07 US US15/742,867 patent/US10413535B2/en not_active Expired - Fee Related
- 2016-07-07 HK HK18106821.2A patent/HK1247120A1/zh unknown
- 2016-07-07 TN TNP/2017/000538A patent/TN2017000538A1/en unknown
- 2016-07-07 CA CA2989522A patent/CA2989522C/en active Active
- 2016-07-07 PL PL16736636T patent/PL3319639T3/pl unknown
- 2016-07-07 ES ES16736636T patent/ES2835274T3/es active Active
- 2016-07-07 MY MYPI2017001928A patent/MY187552A/en unknown
- 2016-07-07 WO PCT/IB2016/054073 patent/WO2017006272A1/en not_active Ceased
- 2016-07-07 MA MA42016A patent/MA42016A1/fr unknown
-
2017
- 2017-12-18 ZA ZA2017/08601A patent/ZA201708601B/en unknown
-
2018
- 2018-01-07 IL IL256770A patent/IL256770B/en active IP Right Grant
- 2018-01-08 CL CL2018000057A patent/CL2018000057A1/es unknown
- 2018-02-08 MA MA44935A patent/MA44935A1/fr unknown
-
2019
- 2019-09-12 US US16/569,465 patent/US10751334B2/en not_active Expired - Fee Related
-
2020
- 2020-04-06 JP JP2020068158A patent/JP2020121985A/ja active Pending
- 2020-07-13 US US16/927,825 patent/US20200405703A1/en not_active Abandoned
-
2021
- 2021-02-11 IL IL280827A patent/IL280827A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2835274T3 (es) | Composiciones farmacéuticas que contienen un antagonista de la integrina alfa 4 para el tratamiento de afecciones inflamatorias oculares | |
| ES2819005T3 (es) | Composición oftálmica para el tratamiento de la enfermedad del ojo seco | |
| ES2675043T3 (es) | Nanotecnología de ciclodextrina para administración de fármaco oftálmico | |
| JP2019518730A (ja) | 眼の炎症性障害および疾患の組合せ処置 | |
| SA521430043B1 (ar) | صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل | |
| JP2021522189A (ja) | 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸 | |
| JP2025061211A (ja) | 自己抗体媒介性眼疾患の治療および診断 | |
| US12268706B2 (en) | Hyaluronic acid for relief of idiopathic ocular pain | |
| EP4167965A1 (en) | Use of high molecular weight hyaluronic acid as ocular transporting vehicle | |
| EP3519050B1 (en) | Compositions for treating ophthalmic conditions | |
| CN107106566A (zh) | 晶状体硬化抑制剂 | |
| US20150307619A1 (en) | Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors | |
| OA19750A (en) | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions. | |
| RU2845362C2 (ru) | Лечение и диагностика опосредованных аутоантителами глазных заболеваний | |
| Agrahari et al. | Recent patents and emerging therapeutics on ocular inflammation and allergy | |
| HK40012460B (en) | Compositions for treating ophthalmic conditions | |
| HK40012460A (en) | Compositions for treating ophthalmic conditions |